

SteveSisolak
Governor

RichardWhitley,MS
Director



DEPARTMENT OF HEALTH AND HUMAN SERVICES

DIVISION OF HEALTH CARE FINANCING AND POLICY

Helping people. It's who we are and what we do.



Suzanne Bierman,
JDMPH
Administrator

June 24, 2021

Inter-Tribal Council of Nevada
Serrell Smokey, ITCN President
Tribal Chairman of Washoe Tribe
919 Highway 395 S
Gardnerville, Nevada 89410

Dear Tribal Members:

In accordance with established consultation guidelines, the Division of Health Care Financing and Policy (DHCFP) is notifying Nevada tribes of the following proposed change in policy:

The DHCFP is proposing revisions to Medicaid Services Manual (MSM) Chapter 1200 – Prescribed Drugs, to reflect recommendations approved on April 22, 2021 by the Drug Use Review (DUR) Board. The proposed changes include the addition of new prior authorization criteria for Nurtec[®] ODT (rimegepant) within the Anti-Migraine Medication section; addition of a new prior authorization for Kesimpta[®] (ofatumumab) within the Multiple Sclerosis (MS) Agents section; revisions to the existing Anti-Hepatitis Agents prior authorization criteria as well as the removal of discontinued products, Daklinza[®] (daclatasvir), Olysio[®] (simeprevir), Technivie[®] (ombitasvir / paritaprevir / ritonavir) and Viekira[®] XR (dasabuvir / ombitasvir / paritaprevir / ritonavir); revisions to the existing Hereditary Angioedema Agents prior authorization criteria; formatting changes to the existing Platelet Inhibitors section; addition of new prior authorization criteria for Xywav[®] (calcium / magnesium / potassium / sodium oxybates) within the Narcolepsy Agents section; and revisions to the existing prior authorization for Valtoco[®] (diazepam nasal spray) within the Anticonvulsants section.

In addition, DHCFP is proposing revisions to Medicaid Services Manual Chapter 1200 - Pharmacy, to reflect the intent of Assembly Bill (AB) 178 from the 81st (2021) Nevada Legislative Session, which allows DHCFP to waive the early refills requirement for a non-controlled substance prescription in areas for which an emergency or disaster has been declared.

There is no anticipated fiscal impact to the Tribal Governments.

If you would like a consultation regarding this proposed change in policy, please contact Crystal Biselli at (775) 684-3722 who will schedule a meeting. We would appreciate a reply within 30 days from the date of this letter. If we do not hear from you within this time, we will consider this an indication that no consultation is requested.

Sincerely,

Handwritten signature of Jessica Kemmerer in cursive.

Jessica Kemmerer
HIPAA Privacy and Civil Rights Officer, DHCFP

Cc: DuAne Young, Deputy Administrator, DHCFP
Cody Phinney, Deputy Administrator, DHCFP
Beth Slamowitz, DHHS Senior Advisor on Pharmacy, DHCFP
David Olsen, Chief of Pharmacy Services, DHCFP
Antonio Gudino Vargas, SSPS III, Pharmacy Services, DHCFP
Briza Virgen, SSPS III, Medical Programs Unit, DHCFP